Dermatology · 2 h ago
POEM Most Closely Correlates With ADCT in Upadacitinib-Treated Atopic Dermatitis
A multicentre retrospective study of 212 patients with moderate-to-severe atopic dermatitis treated with upadacitinib compared disease control scores with patient-reported outcomes over 52 weeks. POEM showed the strongest correlation with ADCT at each assessment, although the findings require prospective confirmation.
- Study included 212 upadacitinib-treated patients.
- All measured outcomes improved from week 4 (p<0.001).
- POEM correlated most strongly with ADCT at each timepoint.
- Prospective studies are needed to confirm the findings.
Researchers conducted a multicentre, retrospective observational study of 212 patients with moderate-to-severe atopic dermatitis treated with upadacitinib. They assessed outcomes at baseline and weeks 4, 16, 32 and 52, examining how the Atopic Dermatitis Control Tool (ADCT) related to patient-reported outcomes used to assess minimal disease activity.
All measured outcomes improved significantly from week 4 onward (p<0.001). An ADCT score below 7, indicating disease control, was recorded in 84.6% of evaluable patients at week 4 and 90.1% at week 52. POEM had the strongest correlation with ADCT at every timepoint (Spearman ρ reported as 0.64), compared with the other patient-reported outcomes assessed.
The results suggest POEM may best reflect patients’ perceived disease control among the measures examined in this treated population. Because the analysis was retrospective and assessed correlations rather than whether one tool improves outcomes, it does not establish that POEM should replace ADCT or guide treatment decisions. The authors call for larger prospective studies to confirm the findings.
In practice
For patients with moderate-to-severe atopic dermatitis treated with upadacitinib, POEM was the patient-reported outcome most closely associated with ADCT-defined control in this retrospective cohort of 212 patients. This supports POEM as a potentially useful complementary measure when assessing patient-perceived disease status, but the study does not establish that it should replace ADCT or direct treatment choices. Its single-treatment context, retrospective design and correlation-based analysis mean prospective confirmation is needed before changing monitoring practice.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Acta Dermato-Venereologica: Explorative Correlation of Atopic Dermatitis Control Tool with Minimal Disease Activity Patient-reported Outcomes in Patients Treated with Upadacitinib: A Retrospective Real-world Study ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.